BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25997881)

  • 21. Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania.
    Mbugi EV; Mutayoba BM; Malisa AL; Balthazary ST; Nyambo TB; Mshinda H
    Malar J; 2006 Oct; 5():94. PubMed ID: 17076899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity.
    Alifrangis M; Enosse S; Khalil IF; Tarimo DS; Lemnge MM; Thompson R; Bygbjerg IC; Rønn AM
    Am J Trop Med Hyg; 2003 Dec; 69(6):601-6. PubMed ID: 14740875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
    Toma H; Imada Y; Vannachone B; Miyagi M; Kobayashi J; Uechi G; Pethuvang R; Manivong K; Phompida S; Sato Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):602-4. PubMed ID: 16124424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Declining trend of Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant alleles after the withdrawal of Sulfadoxine-Pyrimethamine in North Western Ethiopia.
    Tessema SK; Kassa M; Kebede A; Mohammed H; Leta GT; Woyessa A; Guma GT; Petros B
    PLoS One; 2015; 10(10):e0126943. PubMed ID: 26431464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
    Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
    Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short report: molecular markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo.
    Cohuet S; Bonnet M; Van Herp M; Van Overmeir C; D'Alessandro U; Guthmann JP
    Am J Trop Med Hyg; 2006 Jul; 75(1):152-4. PubMed ID: 16837723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia.
    Gebru-Woldearegai T; Hailu A; Grobusch MP; Kun JF
    Am J Trop Med Hyg; 2005 Dec; 73(6):1131-4. PubMed ID: 16354825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
    Kyabayinze D; Cattamanchi A; Kamya MR; Rosenthal PJ; Dorsey G
    Am J Trop Med Hyg; 2003 Sep; 69(3):247-52. PubMed ID: 14628939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology.
    Alifrangis M; Enosse S; Pearce R; Drakeley C; Roper C; Khalil IF; Nkya WM; Rønn AM; Theander TG; Bygbjerg IC
    Am J Trop Med Hyg; 2005 Feb; 72(2):155-62. PubMed ID: 15741552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea.
    Reeder JC; Rieckmann KH; Genton B; Lorry K; Wines B; Cowman AF
    Am J Trop Med Hyg; 1996 Aug; 55(2):209-13. PubMed ID: 8780462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of mutations associated with higher levels of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Car Nicobar Island and Assam, India.
    Ahmed A; Lumb V; Das MK; Dev V; Wajihullah ; Sharma YD
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3934-8. PubMed ID: 16982787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
    Mockenhaupt FP; Teun Bousema J; Eggelte TA; Schreiber J; Ehrhardt S; Wassilew N; Otchwemah RN; Sauerwein RW; Bienzle U
    Trop Med Int Health; 2005 Sep; 10(9):901-8. PubMed ID: 16135198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.
    Kublin JG; Dzinjalamala FK; Kamwendo DD; Malkin EM; Cortese JF; Martino LM; Mukadam RA; Rogerson SJ; Lescano AG; Molyneux ME; Winstanley PA; Chimpeni P; Taylor TE; Plowe CV
    J Infect Dis; 2002 Feb; 185(3):380-8. PubMed ID: 11807721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Progress of researches on genes associated with sulfadoxine-pyrimethamine resistance in
    Qi-Cheng Z; Feng L
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2019 Apr; 31(3):346-348. PubMed ID: 31544425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergence of sulfadoxine-pyrimethamine resistance in Indian isolates of Plasmodium falciparum in the last two decades.
    Kumar A; Moirangthem R; Gahlawat SK; Chandra J; Gupta P; Valecha N; Anvikar A; Singh V
    Infect Genet Evol; 2015 Dec; 36():190-198. PubMed ID: 26319997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia.
    Al-Farsi HM; Al-Hashami ZS; Bin Dajem SM; Al-Sheikh AA; Al-Qahtani A; Beja-Pereira A; Idris MA; Babiker HA
    Infect Genet Evol; 2012 Aug; 12(6):1253-9. PubMed ID: 22709478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection and synergy in Plasmodium falciparum.
    Sims P; Wang P; Hyde JE
    Parasitol Today; 1999 Apr; 15(4):132-4. PubMed ID: 10322332
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine.
    Bacon DJ; Tang D; Salas C; Roncal N; Lucas C; Gerena L; Tapia L; Llanos-Cuentas AA; Garcia C; Solari L; Kyle D; Magill AJ
    PLoS One; 2009 Aug; 4(8):e6762. PubMed ID: 19707564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy.
    Aubouy A; Jafari S; Huart V; Migot-Nabias F; Mayombo J; Durand R; Bakary M; Le Bras J; Deloron P
    J Antimicrob Chemother; 2003 Jul; 52(1):43-9. PubMed ID: 12805261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-grade sulfadoxine-pyrimethamine resistance in Plasmodium falciparum parasites from Lubango, Angola.
    Kaingona-Daniel EP; Gomes LR; Gama BE; Almeida-de-Oliveira NK; Fortes F; Ménard D; Daniel-Ribeiro CT; Ferreira-da-Cruz Mde F
    Malar J; 2016 Jun; 15():309. PubMed ID: 27267365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.